Chronic Kidney Disease

Nearly 35% of patients with advanced chronic kidney disease experienced a deterioration in nutritional status in the course of a year, according to research conducted across six European countries.

Akebia Therapeutics Inc. recently announced the FDA accepted its filing of a new drug application for vadadustat for the treatment of anemia in patients with chronic kidney disease.

Investigators from New York University have identified the plant-based milks that compare most favorably to dairy milk for patients with chronic kidney disease, as well as those prone to kidney stones.

Ziltivekimab, a novel interleukin-6 ligand inhibitor, significantly reduced multiple inflammatory and thrombotic biomarkers associated with atherosclerosis, according to data presented at the American College Cardiology Scientific Session.

Patients with cirrhosis had a higher abundance of beta-lactamase, vancomycin and quinolone genes in their gut microbiota compared with patients with inflammatory bowel disease, chronic kidney disease and diabetes, according to a presentation from Digestive Diseases Week.

The prevalence of chronic kidney disease among Black adults doubled when race adjustment was excluded from eGFR equations, according to a study.

Finding that protein-energy wasting was prevalent in children with kidney disease, researchers outlined what they deemed to be the “most useful” methods for making accurate diagnoses of the condition in this patient population.

An article suggesting thrice weekly doses of cinacalcet could manage certain aspects of bone and mineral metabolism in patients with chronic kidney disease who need treatment with dialysis appeared in Nephrology News and Issues.1

Increases in urinary albumin-creatinine ratio and decreases in estimated glomerular filtration rate heighten the risk for advanced chronic kidney disease, according to a study.

In a cohort of Chinese patients with normal kidney function at baseline, NSAIDs had varying impacts on eGFR decline, with ibuprofen posing the lowest risk and etoricoxib posing the highest risk.